Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene and BioInvent receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors
information fournie par Boursorama CP 27/05/2021 à 08:30

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announce that their Investigational New Drug (IND) application for BT-001 has been granted by the U.S. Food and Drug Administration (FDA). This IND will allow patients in the U.S. to be enrolled into the ongoing Phase I/IIa clinical trial of this novel oncolytic virus BT-001. BT-001 is armed with both a differentiated Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF.

The ongoing Phase I/IIa (NCT04725331) study is a multicenter, open label, dose-escalation trial evaluating BT-001 as a single agent and in combination with pembrolizumab (anti-PD-1 treatment). The Phase I part of the trial has already been initiated in Europe, where it is enrolling patients in several countries.

Valeurs associées

TRANSGENE
0,7470 EUR Euronext Paris -0,66%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
2CRSI
22 -13,39%
Pétrole Brent
78,3 -2,59%
CAC 40
8 400,11 -0,25%
SOITEC
129,45 +9,24%
SOCIETE GENERALE
78,92 +1,61%
Chargement...

Pages les plus populaires

L'offre BoursoBank